Plus   Neg

Anika Therapeutics Inc. (ANIK) Is Sinking On Phase 3 Study Results

Anika Therapeutics Inc. (ANIK) announced after the bell Tuesday that its Phase 3 study of CINGAL 16-02 in patients with knee osteoarthritis failed to reach statistical significance in terms of the primary endpoint.

Anika Therapeutics gapped open sharply lower Wednesday morning and is now down 15.19 at $30.92 on strong volume. The stock has dropped to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT